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B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA-ASSOCIATED  
NUCLEAR ANTIGENS
A bstract: One- and two-dimensional polyacrylamide gel electrophoresis were used to compare 
the composition of nuclear polypeptides from normal and В-cell chronic lymphocytic leukemia 
mononuclear cells. Against two electrophoretically-specific nuclear proteins with molecular weight 
o f 38/39 and 44/46 kDa from leukemic cells rabbit sera were obtained. As it was analyzed by 
Western blot technique the available antisera recognized the 38/39 kDa antigen in 53 of the 56 
(94.6%), while the 44/46 kDa in 46 of the 49 (93.9%) of examined В-CLL nuclear fraction 
preparations, but not in normal ones. The pi values of described leukaemia-specific antigens were 
determined; p38/39 had pi in the range of pH 6.55-7.00  and p44/46 -  in the range of pH 6.2-6.4.
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1. IN TR OD UC T ION
B-cell chronic lymphocytic leukemia (B-CLL) is a hematological cancer 
characterized by an accumulation in blood, bone marrow and lymph nodes, 
transformed clone of В lymphocytes ( R o z m a n ,  M o n s e r r a t  1990; G a l e  et al. 
1994). The etiology of this disease is still not fully understood. It was stated 
that the malignant cells appearing in peripheral blood of patients seems to have 
a low rate of proliferation and resistance to programmed cell death ( Z w i e b e l ,  
CHESON 1998). The remarkable clinical variability in the course of this leukemia 
was observed. These diversities could be a consequence of many cytogenetic 
abnormalities found in B-CLL cells. Although, a variety of genetic aberrations 
have been described, the deletion of chromosome 13 arm (13ql4), as well as 
deletions of chromosome bands 1 lq22.3—23.1, and the trisomy of chromosome
12 are most common ( H a m b l i n ,  O s c i e r  1997; R e e d  1998). Interestingly, the 
deletions involving of chromosome bands 17p 13 and 11 q22.3—23.1 seems to 
correlate with higher B-CLL aggressiveness, shorter survival and resistance to 
therapy (JU LIU SSON, M E R UP 1990; DÖHNER et al. 1999, 2000). These genetic 
alterations occurred in neoplastic B-lymphocytes could lead to changes in the 
level of protein expression or the appearance of new polypeptides on cell 
surface as well as among cellular compartments of transformed B-cells.
Our previous investigations ( C h r u ś c i e l  et al. 1996, 1999; K i l i a ń s k a  et 
al. 1998, 2001) revealed that within nuclei of mononuclear cells isolated 
from peripheral blood samples of B -C L L  patients took place specific expres-
sion of non-histone proteins with a mol. mass of 38/39 and 44/46 kDa 
described as p38/39 and p44/46. Similar nuclear proteins were also detected 
in mononuclear cells obtained from the blood of patients with acute lym- 
phoblastoid leukemia (A L L ) ,  but not from the blood of patients with T-cell 
chronic lymphocytic leukemia (T - C L L )  or healthy donors ( C h r u ś c i e l  et al.
1999).
In present report our special interest is focused on electrophoretic and 
immunological investigation of nuclear proteins from normal and leukemic 
mononuclear cells. Using the rabbit polyclonal antisera raised against 38/39 
and 44/46 kDa polypeptides we verified the appearance of these nuclear 
components among large number of B-CLL mononuclear cell preparations as 
well as normal ones.
2. M A TE RIAL S AND M ET HODS
2.1. Patients and mononuclear cells isolation
Peripheral blood samples were obtained from 63 B-CLL patients aged from 
43 to 83 years. Diagnosis was made in all cases according to standard clinical, 
cytological and immunological criteria. Clinical staging was performed according 
to the Rai classification ( R a i  et al. 1975). Number of patients, i.e., 7, 12, 11, 
10, 21 were stage 0, I, II, III and IV, respectively. Additionally, 2 patients 
were without classification data. All patients had documented lymphocytosis 
with an absolute leukocyte count greater than 15 000/pl and had more than 
30% of lymphocytes in the bone marrow. None of the patients were treated 
before or during the study. Peripheral blood mononuclear cell suspensions were 
obtained by density gradient cell separation using Ficoll-Paque and centrifugation 
(400xg, 18°C, 30 min) according to BÖYUM  method (B Ö YU M  1968). The study 
was approved by the Local Ethics Committee of Medical University of Lodz 
(no. RNN 970/98) and the patients had signed the informed consent form.
Blood samples of healthy donors were used as controls. Mononuclear cells 
were counted by hemocytometer and subjected to isolation of nuclear fraction.
2.2. Morphological and cytochemical studies
Smears of peripheral blood and aspirates of bone marrow were stained with 
May-Grünwald-Giemsa, for peroxidase, a-naphtyl butyrate esterase and with 
periodic-acid Schiff (PAS) solution by standard methods.
2.3. Immunophcnotypic analysis
A panel of monoclonal antibodies was used for immunologic typing including 
CD2, CD3, CD5, CD7, CD9, CD 10, CD20, CD23, TdT, FMC7 (Dakopatts, 
Denmark), conjugated fluorescein isothiocyanate or phycoerythin fluorochromes. 
Surface antigens of the mononuclear cells on all the peripheral blood and bone 
marrow were analyzed by two colours flow cytometer Coulter Epics (Coulter, 
Hialeah). A minimum of 10 000 cells were analyzed per sample and data were 
collected in list mode and examined with the XL2 and Immuno 4 program 
(Coulter).
2.4. Preparation of nuclear fraction
Nuclei were isolated from leukemic and normal mononuclear cells by the 
sucrose method ( B l o b e l ,  P o t t e r  1966) using 0.5% Triton X-100 to remove 
membrane ghost and 1 mM phenylmethyl sulfonyl fluoride (PMSF) to inhibit 
protease activity.
2.5. One-dimensional SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Nuclear protein preparations isolated from 63 individual patients’ blood 
samples were mixed with 0.9 vol of solubilizing buffer [10% glycerol, 4% 
sodium dodecyl sulfate (SDS), 25 jxg pyronine Y, 125 mM Tris-HCl, pH 6.8, 
1 mM PMSF], with 0.1 vol of 2-mercaptoethanol, and heated in boiling water 
for 5 min. The polyacrylamide gel electrophoresis was performed as described 
by L a e m m l i  (1970) at 15 mA slab until the pyronine Y marker reached the 
end of the 3.0% stacking gel and then at 30 mA/slab in the 11.2% resolving 
gel until the marker dye reached the bottom of gel. About 20 (ig of proteins 
were loaded per slot. The proteins were stained with silver nitrate ( W r a y  et
al. 1981). The approximate relative molecular mass (Mr) was determined by 
comparing the mobilities of proteins to those of known molecular mass standards 
(Sigma Chemical Co.).
2.6. Two-dimensional polyacrylamide gel electrophoresis (2-DE)
Two-dimensional electrophoresis was carried out according to the method 
of O ’F a r r e l l  (1975) as modified by CUPO et al. (1990). The first-dimensional 
equilibration isoelectrofocusing gel containing a 2.0% total carrier ampholyte 
mixture (composed of pH range 4.0-6.5, 6.5-9.0 and 3.0-10.0). The final 
acrylamide concentration was 4.0% with a cross-linking of 2.5% N,N’me- 
thylenebisacrylamide. The detergent present in the gel was 0.025 M 3-[3- 
-cholamidopropyl]-dimethylammonio-l-propanesulfonate (CHAPS). Nuclear pro-
tein preparations obtained from 17 individual patients’ blood samples were 
solubilized in 8.0 M urea, 2.0% carrier ampholytes, 0.065 M dithiotreitol, 0.5% 
Nonidet P-40, 0.065 M CHAPS and the samples of about 200 ^g were overlaid 
on the gels. The gels were electrophoresed for 14 hrs at 300 V and for 2 hrs 
at 400 V. The electrolyte solutions were: 0.02 M NaOH (cathode) and 0.01 
M H3P 04 (anode). The pH of the “ blank gels” was measured at 0.5 cm 
intervals in 0.01 M KC1 using a Beckman pH-meter. After isoelectric focusing, 
the gels were equilibrated for 30 min in 10.0% glycerol, 5.0% 2-mercaptoethanol, 
2.3% SDS, and 0.065 M Tris-HCl at pH 6.8. Electrophoresis in the second 
dimension was carried out on 11.2% polyacrylamide gel according to L a e m m li  
(1970). Proteins were visualized by silver staining (W R A Y  et al. 1981).
2.7. Antisera production
New Zealand white rabbits were immunized with В-CLL electrophoretically- 
specific non-histone protein bands visualized after SDS-PAGE by silver staining 
method ( W r a y  et al. 1981) as was described previously ( C h y t i l  1978; C h r u ś -
c i e l  et al. 1996, 1999; KILIAŃSKA et al. 1998). The gel slices were equilibrated 
in 50 mM Tris-HCl buffer (pH 8.0) for 30 min and after cutting into 1 mm 
pieces emulsified in a sterile mortar with an equal volume of 0.9% NaCl and 
complete Freund’s adjuvant for the first immunization and incomplete Freund’s 
adjuvant for the following schedule. Approximately 500 [il (containing 
250-500 (ig) of p38/39 or p44/46 proteins were injected at multiple sites 
intradermally on day zero. The rabbits were boosted at weekly intervals for 
four weeks. The rabbits were bled 1 week after the final injection and the 
sera were assayed for antibodies by immunoblotting technique. The rabbits were 
bled prior to the antigens injection, and the sera were used for control studies. 
No cross reactivity was observed in the presence of preimmune rabbit serum.
2.8. Immunoblotting assay
Electrophoretically separated proteins by SDS-polyacrylamide gel electro-
phoresis or 2-DE were blotted to Immobilon P according to TOW BIN and 
colleagues (TO W B IN  et al. 1979). For immunodetection of antigens immobilized 
on Immobilon P the alkaline phosphatase technique was used. The filters were 
incubated for 1 h at room temperature in 3.0% nonfat dry milk in TBS 
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl) to saturate the non-specific protein 
binding sites. Immobilon filters were incubated with primary antisera (at 1:200) 
dilution) in TBS in a cold room overnight. After washing several times in 
TBS containing 0.05% Tween 20 (TBST), the filters were incubated with goat 
anti-rabbit immunoglobulin conjugated with alkaline phosphatase (Sigma Che-
mical Co.) at 1:6000 dilution in TBS for 2 hrs at room temperature. After 
washing with TBST, specific antigen-antibody reactions were visualized by 
incubation with substrate solution (0.33 mg/ml of nitro blue tétrazolium, 0.17 
mg/ml of 5-bromo-3-chloro-3-indoIyl phosphate in ,'00 mM Tris-HCl, pH 9.5, 
100 mM NaCl and 5 mM MgCl2), prepared according to LEARY et al. (1983).
2.9. Analytical procedures
The protein content for SDS-PAGE technique was estimated by the method 
of L o w r y  ( L o w r y  et al. 1951), while for 2-DE by the method of R a m a g l i  
and R o d r i q u e s  (1985).
3. RE SUL TS AND DISCUSSION
B-cell chronic lymphocytic leukemia is the most common adult leukemia in 
Western World with an annual incidence rate of 3-5 cases per 100 000 ( R a d a e l -  
Ll et al. 2004; ROB AK 2005). The disease affects males more frequently than 
females and usually occurs in older individuals; about 90% of cases are seen in 
people who are 50 years or older, with median age of 65 years at diagnosis 
(Diehl et al. 1999). The course of B-CLL is highly variable and is dependent on 
the stage of disease at diagnosis and the presence or absence of certain clinical, 
biological and molecular risk factors. However, although a number of routine 
hematopoietic cell markers is known, the clinical course and treatment response 
of B-CLL patients is often unpredictable (Z W IEBEL , CHESON 1998). A search for 
new markers might be useful in a more precise determination of control 
lymphocyte differentiation and sufficient for precise classification of lymphoproli- 
ferative disorders. The neoplastic transformation of lymphoid cells is associated 
with genetic alterations leading to changes in the expression of some proteins or 
the expression of novel proteins ( D e l - G i g l i o  et al. 1992; S a u n d e r s  et al. 1994a, 
b; H a n a u s e k  et al. 1996; S c h r o e r s  et al. 2005).
Fig. 1: ( l )  -  SDS-polyacrylamide gel (11.2% resolving gel) electrophoresis o f nuclear proteins 
(about 20 |ig) from normal (N) and leukemic (B-CLL) mononuclear cells followed by silver 
staining; (2 ) - 2-DE of nuclear proteins (~200[ig) from normal (N) and leukemic (B-CLL) mono-
nuclear cells followed by silver staining.
Our previous investigations revealed some differences in electrophoretic 
pattern of cellular compartment proteins, especially isolated from nuclei 
of leukemic (CLL and ALL) cells and those from normal cells of peripheral 
blood ( C h r u ś c i e l  et al. 1996, 1999; K i l i a ń s k a  et al. 1998). In present 
study we have concentrated on electrophoretic and immunological characteri-
zation of nuclear proteins originating from mononuclear cells from blood of 
B-CLL patients and healthy donors. The results obtained by us shown 
some differences in one- and two-dimensional gel electrophoretic patterns of 
nuclear proteins isolated from normal and B-CLL mononuclear cells 
(Fig. 1). Profound analysis of electrophoretic behavior of nuclear proteins 
obtained from control and leukemic cells confirmed many common components, 
however some differences were observed. Main diversities have seen in elect-
rophoretic banding of nuclear proteins from normal and transformed cells, 
particularly in the region of gels with molecular mass of 38-46 and 62-105 
kDa. Moreover, a few constituents characterized by molecular mass of 38/39 
kDa and 44/46 kDa in slightly acidic/neutral area of gels as well as large 
complex of polypeptides with molecular weights/pi of 14-16/5.9-7.4; 
35-36/6.2-7.4; 40-52/5.0-5.6; 64-69/5.1-5.7 and 95-105/5.2-5.5 showed altered 
expression in nuclei of transformed cells during disease development ( R o g a l i ń -
s k a  et al. 2001).
Fig. 2: Immunoblot analysis o f nuclear proteins from normal (N) and leukemic (B-CLL) 
mononuclear cells, by alkaline phosphatase method in the presence of antisera raised against 
electrophoretically-specific polypeptides with Mr of 38/39 kDa ( l )  and 44/46 kDa (2) separated 
from B-CLL nuclear fraction. The symbols indicate the presence (*) or lack (#) o f the p38/39 
and p44/46 antigens, respectively.
Using polyclonal antisera raised against two electrophoretically-specific 
nuclear proteins of leukemic cells with molecular mass of 38/39 and 44/46 
kDa we confirmed by Western blot method the expression of both antigens 
with high frequency among studied leukemic cell preparations. The exem-
plary immunoblot analysis of nuclear proteins from B-CLL and control mo-
nonuclear cells obtained by alkaline phosphatase method in the presence of 
antisera raised against nuclear antigens (p38/39, p44/46) is illustrated on 
Fig. 2. In the study reported here we detected the antigen with molecular 
mass 38/39 kDa (p38/39) in 53 of the 56 (94.6%), and the 44/46 kDa 
(p44/46) -  in 46 of the 49 (93.9%) of the examined B-CLL nuclear fraction 
preparations, but not in any of samples from healthy donors (Table 1). For 
further characterization of both leukemia-specific antigens we employed two- 
dimensional gel electrophoresis (2-DE) of leukemia nuclear proteins followed 
by Western blot analysis in the presence of available anti-p38/39 and anti- 
-p44/46 sera (Fig. 3). As stated by this combined 2DE/Westem blot tech-
niques leukemia-specific antigen p38/39 indicated isoelectric point (pi) in 
the range of pH 6.55-7.00, while the p44/46 -  in the range of pH 6.2-6.4. 
The data described here provide a basis for the supposition that the detected 
nuclear antigens -  p38/39/pI 6.55-7.00 and p44/46/pI 6.2-6.4 whose expres-
sion seems to accompany the transformation of normal mononuclear cells 
into B-CLL cells may serve as potential biomarkers of this type of leu-
kemia.
T a b le  1: Immunodetection of p38/39 and p44/46 antigens among control and B-CLL nuclear 
fraction preparations. Immunodetection of p 3 8 /3 9  was performed among nuclear fraction preparations 
isolated from B-CLL mononuclear cells o f patients classified by Rai’s system: stage 0 - 5 ,  stage 
1 - 1 2 ,  stage II -  11, stage III -  8, and stage IV -  20 patients.
Immunodetection of p 4 4 /4 6  was done among nuclear fraction preparations isolated from B-CLL 
mononuclear cells of patients classified by Rai’s system: stage 0 - 4 ,  stage I -  11, stage II -  8, 
stage III -  8, and stage IV -  16 patients, and 2 patients without staging data.
Control nuclear fraction preparations were obtained from blood of healthy donors.
N um ber of B-C LL Positive N um ber of contro l Positive
Antigen nucle ar fraction reactions nu clear frac tion reactions
prep aratio ns (% ) pre para tion s (% )
p38/39 56 53 (94.6%) 19 0
p44/46 49 46 (93.9%) 11 0
Fig. 3. Immunoblot analysis of nuclear proteins from B-CLL mononuclear cells resolved by 
2 -D E  technique, by alkaline phosphatase method in the presence of antisera raised against elect- 
rophoretically-specific polypeptide p38/39 ( l )  and p44/46 (2).
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